“…No Type I, III or IV endoleak, AAA enlargement, AAA rupture, stent fracture, migration, or endovascular or surgical reintervention were reported during the follow-up period. 31 These results are comparable to ours (all-cause and AAA-related mortality 0%, technical success rate 95%, midterm clinical success rate 94%, no Type I, III, IV endoleak, no migration, open conversion required in 3% of patients), indicating overall promising results, with excellent demonstrated safety and effectiveness in patients with AAA. The two cases that needed conversion to open surgery were performed with the firstgeneration Ovation device and looking retrospectively back it is our belief that in at least one of these patients cannulation would have been feasible with the second-generation Ovation Prime™, in which the limbs are attached at the distal end to facilitate easier catheterization of the contralateral limb.…”